Lundbeck receives marketing authorization for Vyepti® (eptinezumab) in South Korea for the preventive treatment of migraine

Approval granted by South Korea's Ministry of Food and Drug Safety (MFDS) Eptinezumab is an anti-calcitonin gene-related peptide (CGRP) monoclonal antibody for the preventive treatment of migraine in adults Authorization supported by the Phase 3 SUNRISE trial conducted in a predominantly...